Insmed (NASDAQ:INSM) Hits New 52-Week High - What's Next?

Key Points

• Insmed, Inc. shares reached a new 52-week high of $166.44 before last trading at $163.94, with significant trading volume of over 1.4 million shares.
• Analysts have provided a mixed review of Insmed, with target price upgrades from major firms like JPMorgan and Goldman Sachs, while Weiss Ratings maintained a "sell" rating.
• The biopharmaceutical company reported a loss of ($1.70) EPS for the last quarter, missing estimates, but achieved revenue of $107.42 million, which was above expectations.

Shares of Insmed, Inc. (NASDAQ:INSM - Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as $166.44 and last traded at $163.94, with a volume of 1464571 shares traded. The stock had previously closed at $162.33.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. JPMorgan Chase & Co. increased their target price on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 20th. Jefferies Financial Group increased their target price on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Insmed in a research note on Wednesday, October 8th. The Goldman Sachs Group increased their target price on Insmed from $121.00 to $196.00 and gave the stock a "buy" rating in a research note on Friday, October 3rd. Finally, Cowen reiterated a "buy" rating on shares of Insmed in a research note on Thursday, October 2nd. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $149.06.

Insmed Stock Up 1.0%

The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The business has a 50-day moving average price of $139.14 and a 200-day moving average price of $102.76. The firm has a market cap of $34.65 billion, a P/E ratio of -28.71 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period in the previous year, the company posted ($1.94) EPS. Insmed's quarterly revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In related news, insider Michael Alexander Smith sold 24,272 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the sale, the insider owned 54,902 shares of the company's stock, valued at $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director directly owned 262,675 shares in the company, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 211,057 shares of company stock valued at $27,438,126 over the last 90 days. Company insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. boosted its position in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares in the last quarter. ORG Partners LLC boosted its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 196 shares in the last quarter. Hilltop National Bank bought a new stake in Insmed during the second quarter valued at about $28,000. FNY Investment Advisers LLC acquired a new stake in Insmed in the second quarter worth about $33,000. Finally, LRI Investments LLC acquired a new stake in Insmed in the second quarter worth about $59,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.